Germline testing for inherited genetic variants is recommended to many people with cancer, yet such useful testing is notably underutilized.

Most Americans use social media, making it a crucial tool in oncology, where new findings, biomarkers, treatments, and trials are presented.

Choosing NGS first rather than Single-Gene Testing in cancer is a financially effective and diagnostically efficient strategy in many cases.

To enroll in clinical trials for targeted cancer therapies, people must be aware of them; thus, raising awareness is vital to enrollment.

Liquid biopsy for cancer is non-invasive and easily repeated, permitting molecular profiling and many other purposes with strong accuracy.

Blood-based biomarkers (BBMs) hold promise for a fast, convenient, and simple means to accurately diagnose Alzheimer's Disease.

We compared awareness in oncologists of selected biomarkers to the prevalence of actionable oncogenic mutations across cancers.

We examined RAS/KRAS trending and awareness for oncologists; results track strongly with the history of scientific KRAS advancements.

We analyzed trending and awareness patterns of NTRK and NTRK-targeting compounds in academic and community oncologists.

Awareness of new and emerging cancer biomarkers and compounds is vital so HCPs will test for and treat molecular oncogenic drivers.

Patient advocacy groups provide support, education, advocacy, and information sharing while including the patient perspective in healthcare.

NGS is useful for diagnosis and prognosis but also for treatment decisions and resistance monitoring yet it is not consistently used.